EHA 2016: The application of JAK inhibitor in the treatment of polycythemia vera and myelofibrosis

EHA 2016: The application of JAK inhibitor in the treatment of polycythemia vera and myelofibrosis

VJHemOnc

3 years
4 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Haifa Kathrin Al-Ali, MD from University of Leipzig, Leipzig, Germany discusses janus kinase (JAK) inhibitors at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. There is only one drug approved, at present, for the treatment of polycythemia vera (PV) and myelofibrosis (MF) - ruxolitinib a JAK 1/JAK 2 inhibitor. Prof Kathrin also discusses pacritinib a JAK 1 inhibitor and momelotinib a JAK 1 and JAK 2 inhibitor. Fedratinib is a JAK 2 inhibitor however developed has been halted due to safety concerns as some patients have developed Wernicke's encephalopathy.
Up Next Autoplay